Sanofi's Lemtrada US/EU filing promises to heat up competition in multiple sclerosis
This article was originally published in Scrip
Executive Summary
Sanofi's Genzyme subsidiary has filed for US and European approval of its treatment for relapsing multiple sclerosis (MS), Lemtrada (alemtuzumab), as per its revised timeline.